Maria Gustafsson1,2, Ulf Isaksson3,4, Stig Karlsson3, Per-Olof Sandman3,5, Hugo Lövheim6. 1. Department of Pharmacology and Clinical Neuroscience, Division of Clinical Pharmacology, Umeå University, 901 87, Umeå, Sweden. maria.gustafsson@umu.se. 2. Department of Community Medicine and Rehabilitation, Geriatric Medicine, Umeå University, 901 87, Umeå, Sweden. maria.gustafsson@umu.se. 3. Department of Nursing, Umeå University, 901 87, Umeå, Sweden. 4. Arctic Research Centre at Umeå University, 901 87, Umeå, Sweden. 5. Department of Neurobiology, Care Sciences and Society, Division of Nursing, Karolinska Institutet, 171 77, Stockholm, Sweden. 6. Department of Community Medicine and Rehabilitation, Geriatric Medicine, Umeå University, 901 87, Umeå, Sweden.
Abstract
PURPOSE: The use of psychotropic drugs to treat behavioral and psychological symptoms among people with dementia has been widely questioned because of its limited efficacy and risk of harmful side-effects. The objectives of this study was to compare the prevalence of behavioral and psychological symptoms and the use of psychotropic drug treatments among old people with cognitive impairment living in geriatric care units in 2007 and 2013. METHODS: Two questionnaire surveys were performed in 2007 and 2013, comprising all those living in geriatric care units in the county of Västerbotten in northern Sweden. A comparison was made between 1971 people from 2007 and 1511 people from 2013. Data were collected concerning psychotropic and antidementia drug use, functioning in the activities of daily living (ADL), cognition, and behavioral and psychological symptoms, using the Multi-Dimensional Dementia Assessment Scale (MDDAS). RESULTS: Between 2007 and 2013, the use of antipsychotic drugs declined from 25.4 to 18.9 %, and of anxiolytic, hypnotic, and sedative drugs from 35.5 to 29.4 %. The prevalence of people prescribed antidepressant drugs remained unchanged while antidementia drug prescription increased from 17.9 to 21.5 %. When controlled for demographic changes, 36 out of 39 behavioral and psychological symptoms showed no difference in prevalence between the years. CONCLUSIONS: The use of antipsychotic, anxiolytic, hypnotic, and sedative drugs declined considerably between 2007 and 2013 among old people with cognitive impairment living in geriatric care units. Despite this reduction, the prevalences of behavioral and psychological symptoms remained largely unchanged.
PURPOSE: The use of psychotropic drugs to treat behavioral and psychological symptoms among people with dementia has been widely questioned because of its limited efficacy and risk of harmful side-effects. The objectives of this study was to compare the prevalence of behavioral and psychological symptoms and the use of psychotropic drug treatments among old people with cognitive impairment living in geriatric care units in 2007 and 2013. METHODS: Two questionnaire surveys were performed in 2007 and 2013, comprising all those living in geriatric care units in the county of Västerbotten in northern Sweden. A comparison was made between 1971 people from 2007 and 1511 people from 2013. Data were collected concerning psychotropic and antidementia drug use, functioning in the activities of daily living (ADL), cognition, and behavioral and psychological symptoms, using the Multi-Dimensional Dementia Assessment Scale (MDDAS). RESULTS: Between 2007 and 2013, the use of antipsychotic drugs declined from 25.4 to 18.9 %, and of anxiolytic, hypnotic, and sedative drugs from 35.5 to 29.4 %. The prevalence of people prescribed antidepressant drugs remained unchanged while antidementia drug prescription increased from 17.9 to 21.5 %. When controlled for demographic changes, 36 out of 39 behavioral and psychological symptoms showed no difference in prevalence between the years. CONCLUSIONS: The use of antipsychotic, anxiolytic, hypnotic, and sedative drugs declined considerably between 2007 and 2013 among old people with cognitive impairment living in geriatric care units. Despite this reduction, the prevalences of behavioral and psychological symptoms remained largely unchanged.
Authors: Tom Declercq; Mirko Petrovic; Majda Azermai; Robert Vander Stichele; An I M De Sutter; Mieke L van Driel; Thierry Christiaens Journal: Cochrane Database Syst Rev Date: 2013-03-28
Authors: J T Hanlon; R D Horner; K E Schmader; G G Fillenbaum; I K Lewis; W E Wall; L R Landerman; C F Pieper; D G Blazer; H J Cohen Journal: Clin Pharmacol Ther Date: 1998-12 Impact factor: 6.875
Authors: Inken Arnold; Kati Straube; Wolfgang Himmel; Stephanie Heinemann; Vivien Weiss; Laura Heyden; Eva Hummers-Pradier; Roland Nau Journal: BMC Pharmacol Toxicol Date: 2017-12-04 Impact factor: 2.483
Authors: Jonas Kindstedt; Sofia Svahn; Maria Sjölander; Eva-Lotta Glader; Hugo Lövheim; Maria Gustafsson Journal: BMJ Open Date: 2020-04-27 Impact factor: 2.692